Journal article
Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma
Abstract
BACKGROUND: Lenalidomide maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM) results in superior progression-free survival and overall survival. However, patients with high-risk multiple myeloma (HRMM) do not derive the same survival benefit from lenalidomide maintenance compared with standard-risk patients. The authors sought to determine the outcomes of bortezomib-based maintenance compared with lenalidomide …
Authors
Bumma N; Dhakal B; Fraser R; Estrada‐Merly N; Anderson K; Freytes CO; Hildebrandt GC; Holmberg L; Krem MM; Lee C
Journal
Cancer, Vol. 129, No. 14, pp. 2179–2191
Publisher
Wiley
Publication Date
July 15, 2023
DOI
10.1002/cncr.34778
ISSN
1097-0142